SubHero Banner

Adcetris® (brentuximab vedotin) – New indication

November 16, 2018 - The FDA announced the approval of Seattle Genetics’ Adcetris (brentuximab vedotin), for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).

Download PDF